首页> 美国卫生研究院文献>other >Establishment of Cell Lines from Both Myeloma Bone Marrow and Plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a Single Patient
【2h】

Establishment of Cell Lines from Both Myeloma Bone Marrow and Plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a Single Patient

机译:来自一名骨髓瘤的骨髓瘤和浆细胞瘤细胞系的建立:SNU_MM1393_BM和SNU_MM1393_SC

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose. We tried to establish clinically relevant human myeloma cell lines that can contribute to the understanding of multiple myeloma (MM). Materials and Methods. Mononuclear cells obtained from MM patient's bone marrow were injected via tail vein in an NRG/SCID mouse. Fourteen weeks after the injection, tumor developed at subcutis of the mouse. The engraftment of MM cells into mouse bone marrow (BM) was also observed. We separated and cultured cells from subcutis and BM. Results. After the separation and culture of cells from subcutis and BM, we established two cell lines originating from a single patient (SNU_MM1393_BM and SNU_MM1393_SC). Karyotype of the two newly established MM cell lines showed tetraploidy which is different from the karyotype of the patient (diploidy) indicating clonal evolution. In contrast to SNU_MM1393_BM, cell proliferation of SNU_MM1393_SC was IL-6 independent. SNU_MM1393_BM and SNU_MM1393_SC showed high degree of resistance against bortezomib compared to U266 cell line. SNU_MM1393_BM had the greater lethality compared to SNU_MM1393_SC. Conclusion. Two cell lines harboring different site tropisms established from a single patient showed differences in cytokine response and lethality. Our newly established cell lines could be used as a tool to understand the biology of multiple myeloma.
机译:目的。我们试图建立临床相关的人类骨髓瘤细胞系,这些细胞系可有助于理解多发性骨髓瘤(MM)。材料和方法。将来自MM患者骨髓的单核细胞通过尾静脉注射到NRG / SCID小鼠中。注射后十四周,肿瘤在小鼠皮下组织发展。还观察到MM细胞植入小鼠骨髓(BM)。我们从皮下组织和BM中分离并培养了细胞。结果。从皮下组织和BM分离并培养细胞后,我们建立了两个来自单个患者的细胞系(SNU_MM1393_BM和SNU_MM1393_SC)。两种新建立的MM细胞系的核型显示四倍体,不同于患者的核型(二倍体),表明克隆进化。与SNU_MM1393_BM相反,SNU_MM1393_SC的细胞增殖是IL-6独立的。与U266细胞系相比,SNU_MM1393_BM和SNU_MM1393_SC显示出对硼替佐米的高度耐药性。与SNU_MM1393_SC相比,SNU_MM1393_BM的杀伤力更高。结论。从单个患者建立的具有不同位点向性的两种细胞系显示出细胞因子反应和致死性的差异。我们新建立的细胞系可以用作了解多发性骨髓瘤生物学的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号